Clinical Trials Logo
  1. Home
  2. Opioid-induced Constipation
  3. NCT03060512

To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation

Opioid Induced Constipation Clinical Trial

Official title:
A Phase IV, Randomized, Multi-Center, Open-Label, Prospective, Crossover Study to Evaluate Patient Preference of Movantik™ Versus Polyethylene Glycol 3350 for Opioid-Induced Constipation (OIC) Treatment

Clinical Trial Summary

The purpose of this study is to determine whether patients with opioid induced constipation prefer treatment with naloxegol (Movantik) or with Polyethylene Glycol 3350.

Clinical Trial Description

This study is a prospective, randomized, open-label crossover study consisting of a 1-week washout period, a 2-week treatment period, another 1-week washout and a final 2-week treatment period. The study will assess the overall patient preference Movantik versus Polyethylene Glycol 3350 for the treatment of their opioid-induced constipation. This study will also evaluate the reasons for patient preference (only among subjects who indicate a preference), patient global impression of change, and change in bowel function over the treatment periods measured by Bowel Function Index. Patient's bowel movement diary will also be collected during the study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03060512
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 4
Start date March 2, 2017
Completion date August 23, 2017
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02813369 - Naloxegol Health Outcome Post Authorisation Safety Study
Completed NCT01957046 - A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC). Phase 4
Completed NCT01401985 - A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC) Phase 2
Completed NCT00984334 - Naloxone SR Capsules in Patients With Opioid Induced Constipation Phase 2
Completed NCT01207427 - Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain Phase 2
Completed NCT01459926 - A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation Phase 2
Terminated NCT01117051 - Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation Phase 3
Completed NCT01109511 - A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy Phase 4
Active, not recruiting NCT02813356 - Naloxegol US PMR CV Safety.
Completed NCT01812733 - Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives N/A
Completed NCT01623609 - Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol Phase 1
Completed NCT02813148 - Naloxegol Drug Utilization Post Authorisation Safety Study
Completed NCT01443403 - A Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy Phase 2
Completed NCT03638440 - Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.